Effects of Tablet Computer-based Cognitive Training in Patients With Idiopathic REM Sleep Behavior Disorder
NCT05256836, Not applicable, Suspended, Seoul National University Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Tablet Computer-based Cognitive Training in Patients With Idiopathic REM Sleep Behavior Disorder | ClinicalTrials.gov |
| NCT number | NCT05256836 | ClinicalTrials.gov |
| Status | Suspended | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Seoul National University Hospital | ClinicalTrials.gov |
| Conditions | REM Sleep Behavior Disorder | ClinicalTrials.gov |
| Interventions | Tablet computer-based cognitive training program | ClinicalTrials.gov |
| First posted | 2022-02-25 | ClinicalTrials.gov |
| Last updated | 2023-04-21 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K) total score | Change from baseline CERAD-K total score at 12 weeks | Z score of total 5 domains (attentive, memory, language, visuospatial and executive functions) | ClinicalTrials.gov |
| Secondary | Change in CERAD-K attention score | Change from baseline CERAD-K attention score at 12 weeks | Scores for each of the 5 domains 1.Attention * Trail making test A (0\~360): higher scores mean a worse outcome * Stroop test (word) (0\~): higher scores mean a better outcome | ClinicalTrials.gov |
| Secondary | Change in CERAD-K memory score | Change from baseline CERAD-K memory score at 12 weeks | Scores for each of the 5 domains 2.Memory * Word registration (0\~30): higher scores mean a better outcome * Word recall (0\~10): higher scores mean a better outcome * Word recognition (0\~10): higher scores mean a better outcome * Constructional recall (0\~11): higher scores mean a better outcome | ClinicalTrials.gov |
| Secondary | Change in CERAD-K language score | Change from baseline CERAD-K language score at 12 weeks | Scores for each of the 5 domains 3.Language \- Boston naming test (0\~15): higher scores mean a better outcome | ClinicalTrials.gov |
| Secondary | Change in CERAD-K visuospatial function score | Change from baseline CERAD-K visualspatial function score at 12 weeks | Scores for each of the 5 domains 4.Visuospatial function \- Constructional behavior (0\~11): higher scores mean a better outcome | ClinicalTrials.gov |
| Secondary | Change in CERAD-K executive function score | Change from baseline CERAD-K executive function score at 12 weeks | Scores for each of the 5 domains 5.Executive function * Trail making test B (0\~300): higher scores mean a worse outcome * Language fluency (0\~): higher scores mean a better outcome * Stroop test (word/color) (0\~): higher scores mean a better outcome | ClinicalTrials.gov |
| Secondary | Change in mini-mental status examination in the Korean version (MMSE-K) score | Change from baseline MMSE-K score at 12 weeks | minimum value: 0, maximum value: 30 (higher scores mean a better outcome) | ClinicalTrials.gov |
| Secondary | Change in Korean version of Montreal Cognitive Assessment (MoCA-K) score | Change from baseline MoCA-K score at 12 weeks | minimum value: 0, maximum value: 30 (higher scores mean a better outcome) | ClinicalTrials.gov |
| Secondary | Change in resting electroencephalography (EEG) power spectrum | Change from baseline EEG power spectrum at 12 weeks | distribution of power into frequency components composing the signal (delta, theta, alpha, beta) | ClinicalTrials.gov |
| Secondary | Change in resting electroencephalography (EEG) weighted phase lag index | Change from baseline EEG weighted phase lag index at 12 weeks | a functional connectivity measure that quantified how consistently 90° (or 270°) phase 'lagging' one EEG signal was compared to another (From 0 to 1, if it is close to 1, the connectivity is high) | ClinicalTrials.gov |
| Secondary | Change in event-related potential (ERP) reaction time | Change from baseline ERP reaction time at 12 weeks | time (ms) from target presentation to button press | ClinicalTrials.gov |
| Secondary | Change in event-related potential (ERP) hit rate | Change from baseline ERP hit rate at 12 weeks | the probability that an old item is either correctly recognized, or not | ClinicalTrials.gov |
| Secondary | Change in event-related potential (ERP) N2 amplitude | Change from baseline ERP N2 amplitude at 12 weeks | The N2 peak (μV) is a fronto-central maximal negativity observed approximately 150-400 ms after stimulus onset | ClinicalTrials.gov |
| Secondary | Change in event-related potential (ERP) time-frequency analysis | Change from baseline ERP time-frequency analysis at 12 weeks | Indicates the power of the EEG frequency at a specific time | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)